Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4534 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.4534 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.4534 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4534 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4534 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.4534 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.4534 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4534 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.4534 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.4534 | 0.4534 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.5821 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PubChem BioAssay. qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.